New drug aims to stop bleeding in Heart-Lung machine patients

NCT ID NCT06118372

Recruiting now Disease control Sponsor: University of Virginia Source: ClinicalTrials.gov ↗

First seen Feb 05, 2026 · Last updated Jun 16, 2026 · Updated 23 times

Summary

This early-stage study tests a single dose of a lab-made clotting protein (recombinant von Willebrand factor) in 12 adults on ECMO who have serious bleeding. The goal is to see if the drug is safe and how the body processes it. ECMO patients often bleed because the machine damages their natural clotting factors.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BLEEDING DISORDER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

UVA Hospital
RECRUITING

Charlottesville, Virginia, 22903, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

BLEEDING DISORDER

Conditions inferred from the trial description

These were inferred from the trial's summary, not listed by the trial registrant.

ACQUIRED VON WILLEBRAND SYNDROME